Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners
Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix products, has announced a significant agreement with Vizient benefiting Southern Strategic Sourcing Partners (S3P). This partnership grants S3P's vast network of 993 acute care facilities access to Elutia’s innovative EluPro™ Antibiotic Eluting BioEnvelope, starting immediately.
EluPro is the first FDA-cleared antibiotic-eluting biologic envelope for use with cardiac implantable electronic devices (CIEDs) and neurostimulators. It combines powerful antibiotics with a natural extracellular matrix that regenerates into the patient’s own tissue, addressing post-surgical challenges such as infection, migration, and skin erosion.
Dr. Randy Mills, CEO of Elutia, highlighted this partnership as a pivotal milestone, marking their second major GPO collaboration ahead of EluPro’s full commercial launch later this month. S3P's network spans over a dozen U.S. states and represents 91 health systems with over $4 billion in annual spend, significantly accelerating Elutia's mission to deliver life-changing technology to more patients.
Elutia (Nasdaq: ELUT), leader nei prodotti biomatrix a rilascio di farmaci, ha annunciato un importante accordo con Vizient a beneficio dei Southern Strategic Sourcing Partners (S3P). Questa partnership offre alla vasta rete di 993 strutture di assistenza acuta di S3P l'accesso all'innovativo EluPro™ Antibiotic Eluting BioEnvelope, a partire da subito.
EluPro è il primo involucro biologico a rilascio di antibiotici approvato dalla FDA per l'uso con dispositivi elettronici impiantabili cardiaci (CIED) e neurostimolatori. Combina potenti antibiotici con una matrice extracellulare naturale che si rigenera nel tessuto del paziente, affrontando sfide post-chirurgiche come infezioni, migrazione ed erosione della pelle.
Il Dr. Randy Mills, CEO di Elutia, ha evidenziato questa partnership come un traguardo fondamentale, segnando la loro seconda importante collaborazione con un GPO prima del lancio commerciale completo di EluPro previsto per questo mese. La rete di S3P si estende su oltre una dozzina di stati statunitensi e rappresenta 91 sistemi sanitari con oltre 4 miliardi di dollari di spese annuali, accelerando significativamente la missione di Elutia di fornire tecnologie rivoluzionarie a un numero maggiore di pazienti.
Elutia (Nasdaq: ELUT), líder en productos biomatrix de liberación de fármacos, ha anunciado un acuerdo significativo con Vizient en beneficio de los Southern Strategic Sourcing Partners (S3P). Esta asociación otorga a la vasta red de 993 instalaciones de atención aguda de S3P acceso al innovador EluPro™ Antibiotic Eluting BioEnvelope, a partir de ahora.
EluPro es el primer sobre biológico con liberación de antibióticos aprobado por la FDA para su uso con dispositivos electrónicos implantables cardíacos (CIED) y neuroestimuladores. Combina potentes antibióticos con una matriz extracelular natural que se regenera en el propio tejido del paciente, abordando desafíos postquirúrgicos como infecciones, migración y erosión de la piel.
El Dr. Randy Mills, CEO de Elutia, destacó esta asociación como un hito fundamental, marcando su segunda colaboración importante con un GPO antes del lanzamiento comercial completo de EluPro a finales de este mes. La red de S3P abarca más de una docena de estados en EE. UU. y representa 91 sistemas de salud con más de 4 mil millones de dólares en gastos anuales, acelerando significativamente la misión de Elutia de ofrecer tecnología que cambie la vida a más pacientes.
Elutia (Nasdaq: ELUT)는 약물 방출 바이오매트릭스 제품의 선두주자로서 Vizient와의 중요한 계약을 발표했으며, 이는 Southern Strategic Sourcing Partners(S3P)에 이익이 됩니다. 이 파트너십은 S3P의 방대한 993개의 급성 치료 시설 네트워크에 Elutia의 혁신적인 EluPro™ Antibiotic Eluting BioEnvelope에 즉시 접근할 수 있는 권한을 부여합니다.
EluPro는 심장 이식 전자 장치(CIED)와 신경 자극기에 사용하기 위해 FDA의 승인을 받은 최초의 항생제 방출 생물학적 장치입니다. 강력한 항생제가 환자의 자체 조직으로 재생되는 자연세포외기질과 결합하여 감염, 이탈 및 피부 침식을 비롯한 수술 후 문제를 해결합니다.
Elutia의 CEO인 Randy Mills 박사는 이번 파트너십을 중대한 이정표로 강조하며, EluPro의 전체 상업적 출시에 앞서 두 번째 주요 GPO 협력을 기록했다고 말했습니다. S3P의 네트워크는 미국의 12개 주 이상을 포함하고 있으며 연간 40억 달러 이상의 지출을 가진 91개의 의료 시스템을 대표하여 Elutia의 사명인 환자에게 생명을 변화시키는 기술을 제공하는 속도를 크게 높이고 있습니다.
Elutia (Nasdaq: ELUT), un leader dans le domaine des produits biomatrix à libération de médicament, a annoncé un accord significatif avec Vizient au bénéfice des Southern Strategic Sourcing Partners (S3P). Ce partenariat permet à l'immense réseau de 993 établissements de soins aigus de S3P d'accéder immédiatement à l'innovant EluPro™ Antibiotic Eluting BioEnvelope.
EluPro est le premier enveloppe biologique à libération d'antibiotiques approuvée par la FDA pour une utilisation avec des dispositifs électroniques implantables cardiaques (CIED) et des neurostimulateurs. Il combine des antibiotiques puissants avec une matrice extracellulaire naturelle qui se régénère dans le tissu du patient, abordant les défis postopératoires tels que les infections, la migration et l'érosion de la peau.
Le Dr. Randy Mills, PDG d'Elutia, a souligné ce partenariat comme un jalon crucial, marquant leur deuxième collaboration majeure avec un GPO avant le lancement commercial complet d'EluPro prévue plus tard ce mois-ci. Le réseau de S3P s'étend sur plus d'une douzaine d'États américains et représente 91 systèmes de santé avec plus de 4 milliards de dollars de dépenses annuelles, accélérant ainsi la mission d'Elutia de fournir des technologies qui changent la vie à un plus grand nombre de patients.
Elutia (Nasdaq: ELUT), ein führendes Unternehmen im Bereich der medikamentenfreisetzenden Biomatrixprodukte, hat eine bedeutende Vereinbarung mit Vizient bekannt gegeben, die den Southern Strategic Sourcing Partners (S3P) zugutekommt. Diese Partnerschaft ermöglicht es dem umfangreichen Netzwerk von 993 Akutpflegeeinrichtungen von S3P, sofort auf Elutias innovativen EluPro™ Antibiotic Eluting BioEnvelope zuzugreifen.
EluPro ist der erste von der FDA zugelassene biologisch abbaubare Umschlag zur Freisetzung von Antibiotika für die Verwendung mit kardialen implantierbaren elektronischen Geräten (CIEDs) und Neurostimulatoren. Es kombiniert leistungsstarke Antibiotika mit einer natürlichen extrazellulären Matrix, die sich in das Gewebe des Patienten regeneriert und postoperative Herausforderungen wie Infektionen, Migration und Hauterosion anspricht.
Dr. Randy Mills, CEO von Elutia, betonte diese Partnerschaft als einen entscheidenden Meilenstein, der die zweite wichtige GPO-Zusammenarbeit vor dem vollständigen kommerziellen Start von EluPro später in diesem Monat markiert. Das Netzwerk von S3P erstreckt sich über mehr als ein Dutzend US-Bundesstaaten und repräsentiert 91 Gesundheitssysteme mit über 4 Milliarden Dollar an jährlichen Ausgaben, was Elutias Mission, lebensverändernde Technologie für mehr Patienten bereitzustellen, erheblich beschleunigt.
- Elutia secures a major agreement with S3P, expanding access to 993 acute care facilities.
- EluPro™ is the first FDA-cleared antibiotic-eluting biologic envelope for CIEDs and neurostimulators.
- Partnership accelerates Elutia's mission ahead of EluPro’s full commercial launch.
- None.
Insights
The GPO agreement with Southern Strategic Sourcing Partners represents a substantial commercial opportunity for Elutia. S3P's network of 993 acute care facilities and
The timing of this second major GPO partnership, coinciding with EluPro's full commercial launch, strategically positions Elutia to capture significant market share in the CIED and neurostimulator space. The first-mover advantage with FDA clearance for antibiotic-eluting biologic envelopes creates a compelling competitive moat. Conservative estimates suggest the addressable market for CIED procedures alone exceeds
This deal removes a important barrier to market penetration by simplifying the procurement process across multiple health systems. The agreement's immediate implementation timeline suggests potential revenue impact as early as Q1 2025.
EluPro's unique dual-action mechanism - combining antibiotic delivery with tissue regeneration - addresses critical unmet needs in device-related procedures. The technology's ability to prevent three major complications (infection, migration and erosion) positions it as a potential new standard of care for CIED and neurostimulator implantations.
The clinical value proposition is compelling: post-surgical infections in CIED procedures can result in device removal, extended hospital stays and significant healthcare costs. A preventive solution that also promotes tissue integration could dramatically improve patient outcomes while reducing healthcare system expenses. Think of it as creating a specialized protective pocket that both guards against bacteria and becomes part of the patient's own tissue.
The partnership with S3P opens access to a substantial portion of the U.S. healthcare market, particularly in regions where CIED procedure volumes are high. This positions Elutia to potentially capture a significant share of the roughly 400,000 annual CIED procedures performed in the US.
SILVER SPRING, Md., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Vizient for the benefit of Southern Strategic Sourcing Partners (S3P), to provide access to Elutia’s innovative EluPro™ Antibiotic Eluting BioEnvelope to S3P’s extensive network of 993 acute care facilities, starting immediately.
EluPro is the world’s first and only antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration for use with cardiac implantable electronic devices (CIEDs) and neurostimulators. Combining powerful antibiotics with a natural extracellular matrix that regenerates into the patient’s own tissue, EluPro addresses critical post-surgical challenges, including infection, migration, and skin erosion, offering a transformative solution for both patients and clinicians.
“We are excited to partner with S3P to expand access to EluPro, our innovative solution for preventing post-surgical device complications,” said Dr. Randy Mills, Chief Executive Officer of Elutia. “This marks a pivotal milestone as we secure our second major GPO partnership ahead of EluPro’s full commercial launch later this month. With SP3’s extensive network spanning over a dozen U.S. states, this collaboration significantly accelerates our mission to deliver life-changing technology to more patients, empowering them to heal and thrive without compromise.”
S3P is a leading healthcare supply chain aggregation group comprised of 91 health systems, representing 993 acute care facilities and over
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning the launch of EluPro, including the timing and anticipated success thereof. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to successfully commercialize, market and sell our newly approved EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the November 2023 sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; and our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2023, as such factors may be updated from time to time in Elutia’s other filings with the SEC, including Elutia’s Quarterly Reports on Form 10-Q, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
FAQ
What does the ELUT agreement with S3P mean for Elutia shareholders?
What is EluPro™ and why is it significant?
When will Elutia's EluPro™ be fully commercially launched?
How does the S3P partnership impact Elutia’s business?
What are the key features of EluPro™?
How large is the network that S3P represents?
